Shilpa Medicare’s arm receives marketing authorizations from UKMHRA for IMATINIB Tablets

02 Nov 2016 Evaluate

Shilpa Medicare’s wholly owned subsidiary - Koanna Healthcare, UK, has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for the IMATINIB TABLETS in multiple strengths of 100 mg and 400 mg.

The marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc. Out of 15 member states the first approval is received from UKMHRA. Approvals from remaining member states will follow.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.



Shilpa Medicare Share Price

544.00 13.65 (2.57%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.